N🟁N

ISOTECHINIKA AND PALADIN SUBMIT VOCLERA(TM) (VOCLOSPORIN) FOR CANADIAN APPROVAL FOR THE TREATMENT OF MODERATE TO SEVERE PSORIAS

  //health-fitness.news-articles.net/content/2010/ .. the-treatment-of-moderate-to-severe-psorias.html
  Published in Health and Fitness on Monday, December 20th 2010 at 5:41 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

Trades on Toronto Stock Exchange - (TSX: ISA)
[ www.isotechnika.com ]

EDMONTON, Dec. 20 /CNW/ - Isotechnika Pharma Inc. (TSX:ISA) and Paladin Labs Inc. (TSX: PLB) announced today that they have submitted the dossier and received screening acceptance for Voclera^TM (voclosporin) for approval in the Canadian market.  Voclera^TM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.

"Voclera™ was discovered by Isotechnika and has been in development since the late 1990's.  This submission is the culmination of almost 15 years of discovery and development into a novel, next generation calcineurin inhibitor," states Dr. Robert Foster, President and CEO of Isotechnika Pharma Inc.  "We believe Voclera™ offers a unique new treatment that is both safe and effective in treating patients with psoriasis, a very debilitating disease."

"Voclera^TM is an innovative product that will provide an alternative treatment for psoriasis for Canadians." said Jonathan Ross Goodman, President and CEO of Paladin Labs.  

Paladin acquired the Canadian commercial rights for Voclera^TM from Isotechnika in June, 2009.  Isotechnika will receive royalties on any sales of Voclera™ in Canada.

Isotechnika continues to develop voclosporin for use in prevention of organ rejection in kidney transplant recipients for the global marketplace. 

About Isotechnika Pharma Inc.

Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of immunomodulating therapeutics that are designed to offer advantages over other currently available treatments.  There is a significant unmet medical need in the treatment of both solid organ transplantation and autoimmune disease.  It is estimated that the market potential will be $3 billion annually in sales for calcineurin inhibitors such as voclosporin in 2010.

Isotechnika Pharma Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika Pharma can be found at [ www.isotechnika.com ] or [ www.SEDAR.com ].

About Paladin Labs

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies.

We seek Safe Harbor.